查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1863426

CRISPR基因編輯市場按類型、應用、最終用戶和交付方式分類——2025-2032年全球預測

CRISPR Gene Editing Market by Type, Application, End User, Delivery Method - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，CRISPR 基因編輯市場將成長至 136.3 億美元，複合年成長率為 17.40%。

主要市場統計數據
基準年 2024 37.7億美元
預計年份：2025年 44.3億美元
預測年份：2032年 136.3億美元
複合年成長率 (%) 17.40%

本文簡要概述了當前的基因編輯生態系統、技術轉折點以及影響近期策略重點的監管趨勢。

基因編輯領域已從學術研究發展成為科學創新與商業性雄心交會的策略要地。 CRISPR相關核酸酶、精確鹼基編輯和遞送技術的最新進展，正推動其在治療、農業和工業生物技術等領域的廣泛應用，加速實用化進程。本文概述了該領域的現狀，並重點介紹了影響開發者、投資者和政策制定者近期優先事項的技術轉折點和監管趨勢。

技術、監管和交付方面的重大突破將重塑治療和農業基因編輯領域的策略重點和競爭優勢。

過去幾年發生的變革性變化正在重新定義各組織在基因編輯領域研發投資和商業化的優先順序。精準編輯技術（例如鹼基編輯和先導編輯）的進步降低了脫靶風險，並擴大了可靶向基因變化的範圍，從而將治療應用從單基因疾病擴展到複雜的多基因疾病和體細胞疾病。同時，具有不同PAM序列要求和切割機制的模組化可編程核酸酶使科學家能夠針對特定基因位點量身定做編輯策略，從而提高設計效率並提升臨床前模型的成功率。

美國近期關稅調整對基因編輯計畫的供應鏈、區域製造地選擇和合作策略的影響

美國宣布的2025年關稅調整，為依賴跨境供應鏈採購基因編輯計畫所需試劑、設備和生物材料的機構帶來了新的營運複雜性。雖然直接影響主要集中在半成品、專用設備和某些生物加工投入品上，但其連鎖反應已波及採購計劃、投入品替代策略和供應商多元化等各個方面。與國際供應商緊密聯繫的公司面臨著更長的前置作業時間和與海關合規及關稅歸類相關的更多行政負擔。

從類型、應用程式和最終用戶交付方式等方面進行觀點，以確定研究重點和商業化管道的優先順序。

了解基因編輯技術及其按應用領域分類的情況，對於協調研發重點、商業策略和投資決策至關重要。按類型分類，研究和產品系列涵蓋鹼基編輯、Cas9、Cpf1、先導編輯、Talen 和 Zfn，每種技術在精確度、靶點覆蓋範圍和操作考慮方面各有不同，這些因素會影響工具的選擇和檢驗管道。基於應用領域，本報告涵蓋農業、工業能源、研發和治療領域。農業領域專注於作物改良和畜牧生產，反映了不同的性狀靶點和監管方法。工業能源領域則強調生物基化學品和生質燃料，其中製程強化和原料最佳化是推動發展的關鍵因素。研發領域分為基礎研究和藥物發現，重點在於從基礎科學到轉化專案的整個流程。治療領域分為體外療法和體內療法。體外療法進一步包括造血幹細胞療法和 T 細胞療法，而體內療法則進一步包括腫瘤治療和罕見遺傳疾病治療。每個子領域都需要不同的發行策略和臨床終點。按最終用戶分類，市場由學術和研究機構、農業相關企業、受託研究機構)以及製藥生物技術公司組成。學術和研究機構又分為公立研究機構和大學，農業相關企業則分為動物用藥品公司和農作物供應公司。 CRO 分為臨床服務和非臨床服務，製藥生物技術公司則分為大型生物技術公司和小型生物技術公司，二者在資源基礎、風險接受度和夥伴關係模式方面存在差異。技術管道按遞送方式分為非病毒載體和載體載體。非病毒載體包括電穿孔、脂質奈米顆粒和物理方法，而載體載體包括質體載體和病毒載體。每種方法在生產、安全性和監管方面都有其獨特的優缺點。

區域間的比較趨勢和策略考量會影響全球臨床試驗設計、生產在地化和監管一致性。

區域趨勢對基因編輯技術的發展、監管策略和商業化時間表產生了深遠的影響。在美洲，生物技術叢集、創業投資和轉化研究基礎設施的密集分佈，為從概念驗證到臨床試驗的快速過渡提供了支持。同時，監管機構也不斷更新指導意見，強調基於風險的評估和病人安全。在歐洲、中東和非洲，監管方式和公眾輿論呈現出分化趨勢，一些地區為基因編輯作物提供了完善的推廣管道，而另一些地區則實施更為嚴格的監管，這就需要靈活的打入市場策略和加強相關人員之間的合作。亞太地區的特點是擁有高產能的製造地、快速擴張的臨床研究網路，以及正在轉向有利於某些市場治療性和農業基因編輯的政策環境的政策框架。

策略行動和夥伴關係生態系統塑造了平台提供者、治療方法開發商和服務機構的競爭優勢。

基因編輯生態系中的公司策略正圍繞著平台實力、遞送能力和監理執行力趨於一致。專注於工具開發（提供核酸酶、編輯器變體和設計軟體）的公司與專注於端到端治療或農業產品開發的公司之間存在著明顯的二元對立。工具提供者透過投資智慧財產權保護、開發者生態系統和開放科學合作來推動技術應用，而下游開發者則優先考慮遞送解決方案、臨床概念驗證和生產規模化。

經營團隊應優先採取的戰術和組織行動，將基因編輯創新轉化為穩健、符合監管要求的商業項目。

基因編輯領域的領導企業應採取一系列優先行動，將科學潛力轉化為永續的商業和臨床優勢。首先，選擇性地投資於與核心治療和農業目標相符的遞送解決方案。優先考慮已驗證的非病毒載體方法用於體外實驗，並確保病毒載體的供給能力，以滿足持久的體內適應症需求。其次，建立監管情報能力，檢驗特定區域的指導意見，並能夠快速調整測試設計、標籤策略和核准後證據生成。第三，實現供應鏈多元化，加速二級供應商和區域供應商的合格，以降低受貿易政策變化和物流中斷影響的風險。

相關利益者、以證據為導向的研究，結合利害關係人訪談、科學文獻綜述、監管分析和基於情境的綜合分析，得出策略性結論。

本研究整合了一手和二手資料，旨在全面了解基因編輯技術的技術、監管和商業性趨勢。一手資料包括與跨職能相關人員進行結構化訪談和研討會，這些利益相關者包括來自學術機構、生物技術公司、農業發展公司和服務供應商的研發負責人、生產專家、監管事務專家和商業負責人。這些訪談和研討會旨在檢驗假設並探索新的最佳實踐，重點關注技術成熟度、交付限制、監管策略和供應鏈風險緩解。

整合技術發展動能、監管演變和營運韌性，以明確基因編輯領域持續進步的策略要務。

總之，基因編輯技術正從實驗性技術發展成為一個多元化的產業，技術細節、遞送創新、監管清晰度和供應鏈韌性將決定最終結果。精準編輯模式和改進的遞送技術正在拓展治療和農業領域可行干預的可能性。不斷完善的監管和公眾參與正在形成一條差異化的發展路徑，這條路徑將獎勵那些能夠將技術嚴謹性、清晰的證據策略和透明的相關人員溝通結合的機構。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 高保真Cas9突變體的進展可減少治療應用中的脫靶效應
  • Prime 編輯平台取得突破性進展：實現遺傳疾病的多鹼基校正
  • 開發用於體內組織特異性CRISPR 療法的非病毒遞送載體
  • AI驅動的CRISPR引導RNA設計工具提高了特異性並最大限度地減少了意外編輯
  • 商業化規模生產符合cGMP標準的CRISPR試劑以滿足臨床試驗需求
  • 監管協調舉措旨在簡化 CRISPR 療法的全球核准流程
  • 將用於治療單核苷酸疾病的鹼基編輯技術整合到臨床流程中。
  • 用於快速照護現場病原體檢測和基因篩檢的新型 CRISPR 診斷技術

第6章美國關稅的累積影響，2025年

第7章 人工智慧的累積影響，2025年

8. CRISPR基因編輯市場按類型分類

  • 基礎編輯
  • Cas9
  • Cpf1
  • Prime Edit
  • 塔倫
  • Zfn

9. CRISPR基因編輯市場按應用領域分類

  • 農業
    • 作物改良
    • 家畜
  • 工業能源
    • 生物基化學品
    • 生質燃料
  • 研究與開發
    • 基礎研究
    • 藥物發現
  • 治療
    • 體外治療
      • 造血幹細胞療法
      • T細胞療法
    • 內科治療
      • 腫瘤學
      • 罕見遺傳疾病

第10章 CRISPR基因編輯市場（按最終用戶分類）

  • 學術和研究機構
    • 公共研究機構
    • 大學
  • 農業相關企業
    • 動物用藥品公司
    • 農作物供應商
  • 受託研究機構
    • 臨床服務
    • 臨床前服務
  • 製藥和生物技術公司
    • 大型製藥企業
    • 中小型生技公司

11. CRISPR基因編輯市場以交付方式分類

  • 非病毒方法
    • 電穿孔
    • 脂質奈米顆粒
    • 物理方法
  • 向量
    • 質體載體
    • 病毒載體

12. CRISPR基因編輯市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 CRISPR基因編輯市場（依群體分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 各國 CRISPR 基因編輯市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Thermo Fisher Scientific Inc.
    • Merck KGaA
    • Danaher Corporation
    • Agilent Technologies, Inc.
    • Qiagen NV
    • New England Biolabs, Inc.
    • Illumina, Inc.
    • GenScript BIoTech Corporation
    • Synthego, Inc.
    • Takara Bio Inc.
Product Code: MRR-5C6F41F5AF91

The CRISPR Gene Editing Market is projected to grow by USD 13.63 billion at a CAGR of 17.40% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 3.77 billion
Estimated Year [2025] USD 4.43 billion
Forecast Year [2032] USD 13.63 billion
CAGR (%) 17.40%

A concise orientation to the current gene editing ecosystem, technological inflection points, and evolving regulatory dynamics shaping near-term strategic priorities

The gene editing landscape has evolved from academic curiosity into a strategic arena where scientific innovation and commercial ambition intersect. Recent advances in CRISPR-associated nucleases, precision base editing, and delivery technologies have accelerated translational pathways, enabling a broad set of applications across therapeutics, agriculture, and industrial biotechnology. This introduction frames the current state of the field, highlighting the technological inflection points and regulatory developments that are shaping near-term priorities for developers, investors, and policy makers.

Technological progress has been accompanied by a maturing ecosystem of service providers, platform companies, and collaborative consortia that de-risk early-stage development and enable scale-up. Simultaneously, regulatory bodies in multiple jurisdictions are refining guidance for gene-edited products, which is creating clearer pathways while also introducing novel compliance obligations. Together, these dynamics are redefining competitive advantage: leaders will be those that pair rigorous science with pragmatic regulatory strategy, robust delivery solutions, and evidence-driven clinical or field validation. This introduction sets the stage for a deeper analysis of transformative shifts, tariff impacts, segmentation insights, regional dynamics, and actionable recommendations for organizations operating in this rapidly changing domain.

Critical technological, regulatory, and delivery breakthroughs reshaping strategic priorities and competitive advantage across therapeutic and agricultural gene editing

The past several years have produced transformative shifts that are redefining how organizations prioritize R&D investment and commercialization in gene editing. Advances in precision modalities such as base editing and prime editing are reducing off-target risk and expanding the set of addressable genetic alterations, which in turn is broadening therapeutic applications beyond single-gene disorders into complex polygenic and somatic indications. Meanwhile, modular programmable nucleases with differing PAM requirements and cleavage mechanics are allowing scientists to tailor editing strategies to specific loci, driving more efficient design cycles and higher success rates in preclinical models.

Concurrently, delivery science has moved from an unresolved bottleneck to a competitive differentiator. Improvements in lipid nanoparticle formulations, electroporation methods, and hybrid non-viral systems are enabling safer and more efficient ex vivo and in vivo interventions. These advances are complemented by increased investment in scalable vector production and manufacturing process intensification, which are critical to translate laboratory successes into clinically and commercially viable products.

Policy and public perception have also shifted. Regulatory agencies are publishing clearer guidance and adopting science-based frameworks; however, the global regulatory topology remains heterogeneous. This unevenness is encouraging parallel development strategies and regionally optimized trial designs. As a result, strategic alliances, cross-sector partnerships, and platform licensing arrangements are becoming a dominant business model to accelerate time-to-evidence and broaden access to capabilities. Together, these shifts suggest a landscape in which speed to reliable clinical or agricultural proof, secure supply chains, and regulatory agility will determine competitive outcomes.

How recent U.S. tariff revisions are reshaping supply chains, regional manufacturing choices, and collaborative research strategies for gene editing programs

Tariff adjustments announced in 2025 by the United States have introduced a new layer of operational complexity for organizations that rely on cross-border supply chains for reagents, equipment, and biological materials integral to gene editing programs. While the immediate impact has been concentrated on intermediate goods, specialized instruments, and certain bioprocess inputs, the reverberations extend to procurement timelines, input substitution strategies, and supplier diversification efforts. Companies with tightly coupled international suppliers have experienced elongation of lead times and an increased administrative burden associated with customs compliance and tariff classification.

In response, many organizations have accelerated regionalization strategies, expanding local sourcing and qualifying multiple vendors across jurisdictions to mitigate exposure. This has led to a reprioritization of capital spend toward local manufacturing capacity, inventory buffers, and onshore production of high-value components. Moreover, tariff-driven cost pressures have elevated the importance of operational excellence initiatives that reduce waste and improve reagent utilization, thereby lowering dependency on high-cost imported materials.

The policy shift has also impacted collaborative research models. Cross-border specimen exchange and collaborative reagent sharing now require more detailed contractual frameworks to address potential cost reallocations and regulatory compliance. Clinical and field trial sponsors are reassessing site selection criteria to account for supply resilience and total program risk. Taken together, the tariff changes have catalyzed strategic realignment across sourcing, manufacturing, and partnership structures, incentivizing greater domestic capacity and more robust supplier governance to preserve program timelines and control costs without diluting scientific rigor.

Integrated segmentation perspectives that connect types, applications, end users, and delivery methods to prioritize research focus and commercialization pathways

Understanding the segmentation of gene editing technologies and applications is essential to aligning R&D priorities, commercial strategies, and investment decisions. Based on Type, research and product portfolios span Base Editing, Cas9, Cpf1, Prime Editing, Talen, and Zfn, each offering distinct precision, target range, and operational considerations that influence tool selection and validation pathways. Based on Application, the field covers Agriculture, Industrial & Energy, Research & Development, and Therapeutic; within Agriculture there is a focus on Crop Improvement and Livestock, reflecting different trait targets and regulatory approaches, while Industrial & Energy applications emphasize Bio-based Chemicals and Biofuels with process intensification and feedstock optimization driving development. The Research & Development segment is differentiated into Basic Research and Drug Discovery, underscoring the pipeline from foundational science to translational programs, and the Therapeutic segment separates Ex Vivo Therapy and In Vivo Therapy, where Ex Vivo Therapy further includes Hematopoietic Stem Cell Therapy and T Cell Therapy and In Vivo Therapy further includes Oncology and Rare Genetic Disorders, each subsegment demanding distinct delivery strategies and clinical endpoints. Based on End User, the ecosystem comprises Academic & Research Institutes, Agricultural Companies, Contract Research Organizations, and Pharma & Biotech Companies, with the Academic & Research Institutes category differentiated into Public Research Institutes and Universities, Agricultural Companies split into Animal Health Companies and Crop Providers, Contract Research Organizations divided into Clinical Services and Preclinical Services, and Pharma & Biotech Companies segmented into Large Pharma and Small & Medium Biotech, which together reflect different resource bases, risk appetites, and partnership models. Based on Delivery Method, technological pathways are categorized into Non-Viral Methods and Vectors; Non-Viral Methods include Electroporation, Lipid Nanoparticles, and Physical Methods while Vectors encompass Plasmid Vectors and Viral Vectors, each with unique manufacturing, safety, and regulatory trade-offs.

Applying these segmentation lenses reveals where scientific innovation intersects with commercial feasibility. For example, precision modalities such as base editing and prime editing are finding rapid adoption in basic research and drug discovery because they reduce the need for complex vector engineering, while viral vectors remain central to many in vivo therapeutic programs that require durable expression. Agricultural applications are bifurcated between crop trait engineering, which can leverage tissue culture and gene drive-adjacent strategies, and livestock applications that prioritize welfare, breeding timelines, and regulatory clarity. End users differ dramatically in procurement cadence and validation expectations: academic centers often prioritize flexibility and open-source tools, whereas large pharmaceutical firms demand validated supply chains, GMP-compliant materials, and comprehensive regulatory dossiers. Finally, delivery method choices are often determined by a program's target cells and required duration of effect, with non-viral approaches increasingly competitive in ex vivo workflows and some in vivo niches due to safety and manufacturing scalability.

Comparative regional dynamics and strategic considerations that influence trial design, manufacturing localization, and regulatory alignment across global jurisdictions

Regional dynamics are exerting a powerful influence on technology development, regulatory strategy, and commercialization timelines in gene editing. In the Americas, a dense concentration of biotechnology clusters, venture capital, and translational research infrastructure supports rapid movement from proof-of-concept to clinical trial initiation, while regulatory agencies are publishing evolving guidance that emphasizes risk-based evaluation and patient safety. Europe, Middle East & Africa presents a mosaic of regulatory approaches and public sentiment, with some jurisdictions offering progressive pathways for gene-edited crops and others applying stricter oversight, necessitating flexible go-to-market strategies and enhanced stakeholder engagement. Asia-Pacific is characterized by a mix of high-capacity manufacturing hubs, rapidly expanding clinical research networks, and policy environments that, in select markets, are moving toward enabling frameworks for both therapeutic and agricultural gene editing.

These regional contrasts are shaping where companies invest in trials, manufacturing capacity, and partnerships. For instance, clinical programs targeting rare genetic disorders may prioritize regions with streamlined orphan drug pathways and access to specialized clinical sites, while agricultural trait developers often select jurisdictions with clearer product differentiation between gene editing and transgenesis. Supply chain resilience considerations are also regional: localized reagent production and contract manufacturing capabilities can mitigate the impact of trade policy shifts and logistics disruptions. Strategic investors and corporate leaders must therefore adopt a regionally nuanced approach that balances speed to evidence, regulatory predictability, manufacturing access, and stakeholder acceptance across the Americas, Europe, Middle East & Africa, and Asia-Pacific to optimize program outcomes.

Strategic behaviors and partnership ecosystems shaping competitive advantage for platform providers, therapeutic developers, and service organizations

Company strategies within the gene editing ecosystem are coalescing around platform strength, delivery capabilities, and regulatory execution. There is a clear bifurcation between organizations that focus on tool development-providing nucleases, editor variants, and design software-and those that concentrate on end-to-end therapeutic or agricultural product development. Tool providers are investing in intellectual property protection, developer ecosystems, and open-science collaborations to drive widespread adoption, while downstream developers are prioritizing delivery solutions, clinical proof-of-concept, and manufacturing scale-up.

Partnership models are increasingly sophisticated: strategic alliances, licensing deals, and co-development agreements enable companies to combine complementary strengths such as vector manufacturing, clinical operations, and regulatory affairs. Service providers and contract research organizations are expanding capabilities to include GMP-grade reagent supply, scalable process development, and regulatory consulting, which reduces time and risk for smaller developers. Investment activity remains robust in platform technologies and delivery innovations, and leadership in commercial outcomes will likely belong to organizations that can integrate high-fidelity editing modalities with validated delivery systems, robust manufacturing processes, and a demonstrated regulatory pathway. Executives should also monitor emerging entrants specializing in niche enabling technologies-such as improved nuclease variants, novel nanoparticle chemistries, and automated cell engineering platforms-that can offer asymmetric advantages to larger integrated players through licensing or acquisition.

Priority tactical and organizational actions executives should implement to convert gene editing innovations into resilient, regulation-ready commercial programs

Leaders in gene editing should adopt a set of prioritized actions that translate scientific promise into durable commercial and clinical advantage. First, invest selectively in delivery solutions that align with core therapeutic or agricultural targets; prioritizing validated non-viral approaches for ex vivo programs and ensuring viral vector capacity for in vivo indications where durability is required. Second, build regulatory intelligence capabilities that track region-specific guidance and enable rapid adaptation of trial design, labeling strategy, and post-approval evidence generation. Third, diversify supply chains and accelerate qualification of secondary vendors and regional suppliers to reduce exposure to trade policy shifts and logistics disruptions.

Beyond operational resilience, organizations should cultivate strategic partnerships that map complementary strengths-combining platform providers' molecular innovation with developers' clinical infrastructure and commercialization experience. Consider flexible commercial models such as staged licensing and milestone-based co-development to share risk and align incentives. Additionally, invest in talent that bridges molecular biology, process engineering, and regulatory science to accelerate translational readiness. Finally, maintain proactive stakeholder engagement programs that communicate safety profiles, benefit-risk trade-offs, and societal value propositions to patients, farmers, regulators, and the public; this will be essential to sustaining social license and mitigating reputational risk as applications expand into new domains.

A transparent and evidence-driven research approach combining stakeholder interviews, scientific literature review, regulatory analysis, and scenario-based synthesis to inform strategic conclusions

This research synthesized primary and secondary inputs to develop a holistic view of technological, regulatory, and commercial dynamics in gene editing. Primary research included structured interviews and workshop sessions with cross-functional stakeholders such as R&D leads, manufacturing experts, regulatory affairs professionals, and commercial strategists drawn from academic institutions, biotechnology companies, agricultural developers, and service providers. These engagements focused on technology readiness, delivery constraints, regulatory strategy, and supply chain risk mitigation, and they were used to validate hypotheses and surface emerging best practices.

Secondary research encompassed peer-reviewed scientific literature, policy statements from regulatory agencies, clinical trial registries, patent filings, company technical disclosures, and industry conference proceedings. Data synthesis prioritized triangulation across sources to ensure robustness and to identify convergent trends versus outlier signals. Scenario analysis was applied to evaluate the implications of regulatory divergence, tariff changes, and delivery technology adoption on program execution. The methodology emphasizes transparency in assumptions and a defensible linkage between technical evidence and strategic implications, enabling decision-makers to adapt recommendations to specific organizational contexts.

Synthesis of technological momentum, regulatory evolution, and operational resilience that defines the strategic imperative for sustained progress in gene editing

In conclusion, gene editing is transitioning from experimental methods to a multifaceted industry where technical nuance, delivery innovation, regulatory clarity, and supply chain resilience determine outcomes. Precision editing modalities and improved delivery technologies are expanding the horizon of feasible interventions across both therapeutic and agricultural domains. Regulatory evolution and public engagement are creating differentiated pathways that will reward organizations capable of aligning technical rigor with clear evidence strategies and transparent stakeholder communication.

Operationally, the combination of tariff-driven supply chain pressures and regional variation in regulatory approaches underscores the necessity of diversified sourcing, regional manufacturing capacity, and agile clinical or field deployment plans. Strategic collaboration remains a cornerstone of progress: platform developers, service providers, and end-product developers must continue to form alliances that accelerate validation and de-risk scale-up. Organizations that invest in delivery platforms, regulatory intelligence, and resilient supply models will be best positioned to translate gene editing capabilities into enduring clinical and commercial impact. The path forward requires an integrated approach that balances scientific excellence with pragmatic execution.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Advancements in high-fidelity Cas9 variants reducing off-target effects in therapeutic applications
  • 5.2. Breakthroughs in prime editing platforms enabling multi-base corrections for genetic diseases
  • 5.3. Development of nonviral delivery vectors for tissue-specific CRISPR therapeutics in vivo
  • 5.4. AI-driven CRISPR guide RNA design tools enhancing specificity and minimizing unintended edits
  • 5.5. Commercial scaling of cGMP manufacturing for CRISPR reagents to support clinical trial demand
  • 5.6. Regulatory alignment initiatives streamlining global approval processes for CRISPR therapies
  • 5.7. Integration of base editing technologies targeting single-nucleotide disorders in clinical pipelines
  • 5.8. Emerging CRISPR diagnostics for rapid point-of-care pathogen detection and genetic screening

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. CRISPR Gene Editing Market, by Type

  • 8.1. Base Editing
  • 8.2. Cas9
  • 8.3. Cpf1
  • 8.4. Prime Editing
  • 8.5. Talen
  • 8.6. Zfn

9. CRISPR Gene Editing Market, by Application

  • 9.1. Agriculture
    • 9.1.1. Crop Improvement
    • 9.1.2. Livestock
  • 9.2. Industrial & Energy
    • 9.2.1. Bio-based Chemicals
    • 9.2.2. Biofuels
  • 9.3. Research & Development
    • 9.3.1. Basic Research
    • 9.3.2. Drug Discovery
  • 9.4. Therapeutic
    • 9.4.1. Ex Vivo Therapy
      • 9.4.1.1. Hematopoietic Stem Cell Therapy
      • 9.4.1.2. T Cell Therapy
    • 9.4.2. In Vivo Therapy
      • 9.4.2.1. Oncology
      • 9.4.2.2. Rare Genetic Disorders

10. CRISPR Gene Editing Market, by End User

  • 10.1. Academic & Research Institutes
    • 10.1.1. Public Research Institutes
    • 10.1.2. Universities
  • 10.2. Agricultural Companies
    • 10.2.1. Animal Health Companies
    • 10.2.2. Crop Providers
  • 10.3. Contract Research Organizations
    • 10.3.1. Clinical Services
    • 10.3.2. Preclinical Services
  • 10.4. Pharma & Biotech Companies
    • 10.4.1. Large Pharma
    • 10.4.2. Small & Medium Biotech

11. CRISPR Gene Editing Market, by Delivery Method

  • 11.1. Non-Viral Methods
    • 11.1.1. Electroporation
    • 11.1.2. Lipid Nanoparticles
    • 11.1.3. Physical Methods
  • 11.2. Vectors
    • 11.2.1. Plasmid Vectors
    • 11.2.2. Viral Vectors

12. CRISPR Gene Editing Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. CRISPR Gene Editing Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. CRISPR Gene Editing Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Thermo Fisher Scientific Inc.
    • 15.3.2. Merck KGaA
    • 15.3.3. Danaher Corporation
    • 15.3.4. Agilent Technologies, Inc.
    • 15.3.5. Qiagen N.V.
    • 15.3.6. New England Biolabs, Inc.
    • 15.3.7. Illumina, Inc.
    • 15.3.8. GenScript Biotech Corporation
    • 15.3.9. Synthego, Inc.
    • 15.3.10. Takara Bio Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CRISPR GENE EDITING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY DELIVERY METHOD, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY DELIVERY METHOD, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS CRISPR GENE EDITING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA CRISPR GENE EDITING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA CRISPR GENE EDITING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA CRISPR GENE EDITING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE CRISPR GENE EDITING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST CRISPR GENE EDITING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA CRISPR GENE EDITING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC CRISPR GENE EDITING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN CRISPR GENE EDITING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC CRISPR GENE EDITING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION CRISPR GENE EDITING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS CRISPR GENE EDITING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 CRISPR GENE EDITING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO CRISPR GENE EDITING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. CRISPR GENE EDITING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. CRISPR GENE EDITING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CRISPR GENE EDITING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CRISPR GENE EDITING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CRISPR GENE EDITING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY BASE EDITING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY BASE EDITING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY BASE EDITING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY BASE EDITING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY BASE EDITING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY BASE EDITING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY CAS9, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY CAS9, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY CAS9, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY CAS9, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY CAS9, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY CAS9, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY CPF1, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY CPF1, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY CPF1, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY CPF1, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY CPF1, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY CPF1, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY PRIME EDITING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY PRIME EDITING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY PRIME EDITING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY PRIME EDITING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY PRIME EDITING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY PRIME EDITING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY TALEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY TALEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY TALEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY TALEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY TALEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY TALEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY ZFN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY ZFN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY ZFN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY ZFN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY ZFN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY ZFN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY AGRICULTURE, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY AGRICULTURE, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY AGRICULTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY AGRICULTURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY AGRICULTURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY AGRICULTURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY AGRICULTURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY AGRICULTURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY CROP IMPROVEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY CROP IMPROVEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY CROP IMPROVEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY CROP IMPROVEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY CROP IMPROVEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY CROP IMPROVEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY LIVESTOCK, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY LIVESTOCK, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY LIVESTOCK, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY LIVESTOCK, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY LIVESTOCK, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY LIVESTOCK, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY INDUSTRIAL & ENERGY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY INDUSTRIAL & ENERGY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY INDUSTRIAL & ENERGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY INDUSTRIAL & ENERGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY INDUSTRIAL & ENERGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY INDUSTRIAL & ENERGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY INDUSTRIAL & ENERGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY INDUSTRIAL & ENERGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY BIO-BASED CHEMICALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY BIO-BASED CHEMICALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY BIO-BASED CHEMICALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY BIO-BASED CHEMICALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY BIO-BASED CHEMICALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY BIO-BASED CHEMICALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY BIOFUELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY BIOFUELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY BIOFUELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY BIOFUELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY BIOFUELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY BIOFUELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY RESEARCH & DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY RESEARCH & DEVELOPMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY RESEARCH & DEVELOPMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY RESEARCH & DEVELOPMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY RESEARCH & DEVELOPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY RESEARCH & DEVELOPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY BASIC RESEARCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY BASIC RESEARCH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY BASIC RESEARCH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY BASIC RESEARCH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY BASIC RESEARCH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY BASIC RESEARCH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY DRUG DISCOVERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY DRUG DISCOVERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY DRUG DISCOVERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY DRUG DISCOVERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY THERAPEUTIC, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY THERAPEUTIC, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY THERAPEUTIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY THERAPEUTIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY THERAPEUTIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY THERAPEUTIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY THERAPEUTIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY THERAPEUTIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY EX VIVO THERAPY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY EX VIVO THERAPY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY EX VIVO THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY EX VIVO THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY EX VIVO THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY EX VIVO THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY EX VIVO THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY EX VIVO THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY HEMATOPOIETIC STEM CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY HEMATOPOIETIC STEM CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY HEMATOPOIETIC STEM CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY HEMATOPOIETIC STEM CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY HEMATOPOIETIC STEM CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY HEMATOPOIETIC STEM CELL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY T CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY T CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY T CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY T CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY T CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY T CELL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY IN VIVO THERAPY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY IN VIVO THERAPY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY IN VIVO THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY IN VIVO THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY IN VIVO THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY IN VIVO THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY IN VIVO THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY IN VIVO THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY RARE GENETIC DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY RARE GENETIC DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY RARE GENETIC DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY RARE GENETIC DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY RARE GENETIC DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY RARE GENETIC DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY PUBLIC RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY PUBLIC RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY PUBLIC RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY PUBLIC RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY PUBLIC RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY PUBLIC RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY UNIVERSITIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY UNIVERSITIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY UNIVERSITIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY UNIVERSITIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY UNIVERSITIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY UNIVERSITIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY AGRICULTURAL COMPANIES, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY AGRICULTURAL COMPANIES, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY AGRICULTURAL COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY AGRICULTURAL COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY AGRICULTURAL COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY AGRICULTURAL COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY AGRICULTURAL COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY AGRICULTURAL COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY ANIMAL HEALTH COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY ANIMAL HEALTH COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY ANIMAL HEALTH COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY ANIMAL HEALTH COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY ANIMAL HEALTH COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY ANIMAL HEALTH COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY CROP PROVIDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY CROP PROVIDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY CROP PROVIDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY CROP PROVIDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY CROP PROVIDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY CROP PROVIDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY CLINICAL SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY CLINICAL SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY CLINICAL SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY CLINICAL SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY CLINICAL SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY CLINICAL SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY PRECLINICAL SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY PRECLINICAL SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY PRECLINICAL SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY PRECLINICAL SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY PRECLINICAL SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY PRECLINICAL SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY PHARMA & BIOTECH COMPANIES, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY PHARMA & BIOTECH COMPANIES, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY PHARMA & BIOTECH COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY PHARMA & BIOTECH COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY PHARMA & BIOTECH COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY PHARMA & BIOTECH COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY PHARMA & BIOTECH COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY PHARMA & BIOTECH COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY LARGE PHARMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY LARGE PHARMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY LARGE PHARMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY LARGE PHARMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY LARGE PHARMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY LARGE PHARMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY SMALL & MEDIUM BIOTECH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY SMALL & MEDIUM BIOTECH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY SMALL & MEDIUM BIOTECH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY SMALL & MEDIUM BIOTECH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY SMALL & MEDIUM BIOTECH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY SMALL & MEDIUM BIOTECH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY NON-VIRAL METHODS, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY NON-VIRAL METHODS, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY NON-VIRAL METHODS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY NON-VIRAL METHODS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY NON-VIRAL METHODS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY NON-VIRAL METHODS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY NON-VIRAL METHODS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY NON-VIRAL METHODS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY ELECTROPORATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY ELECTROPORATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY ELECTROPORATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY ELECTROPORATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY ELECTROPORATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY ELECTROPORATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY LIPID NANOPARTICLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY LIPID NANOPARTICLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY LIPID NANOPARTICLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY LIPID NANOPARTICLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY LIPID NANOPARTICLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY LIPID NANOPARTICLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY PHYSICAL METHODS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY PHYSICAL METHODS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY PHYSICAL METHODS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY PHYSICAL METHODS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY PHYSICAL METHODS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY PHYSICAL METHODS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY VECTORS, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY VECTORS, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY VECTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY VECTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY VECTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY VECTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY VECTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY VECTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY PLASMID VECTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY PLASMID VECTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY PLASMID VECTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY PLASMID VECTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY PLASMID VECTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY PLASMID VECTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY VIRAL VECTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY VIRAL VECTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY VIRAL VECTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY VIRAL VECTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY VIRAL VECTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY VIRAL VECTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL CRISPR GENE EDITING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 285. AMERICAS CRISPR GENE EDITING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 286. AMERICAS CRISPR GENE EDITING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 287. AMERICAS CRISPR GENE EDITING MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 288. AMERICAS CRISPR GENE EDITING MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 289. AMERICAS CRISPR GENE EDITING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 290. AMERICAS CRISPR GENE EDITING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 291. AMERICAS CRISPR GENE EDITING MARKET SIZE, BY AGRICULTURE, 2018-2024 (USD MILLION)
  • TABLE 292. AMERICAS CRISPR GENE EDITING MARKET SIZE, BY AGRICULTURE, 2025-2032 (USD MILLION)
  • TABLE 293. AMERICAS CRISPR GENE EDITING MARKET SIZE, BY INDUSTRIAL & ENERGY, 2018-2024 (USD MILLION)
  • TABLE 294. AMERICAS CRISPR GENE EDITING MARKET SIZE, BY INDUSTRIAL & ENERGY, 2025-2032 (USD MILLION)
  • TABLE 295. AMERICAS CRISPR GENE EDITING MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2024 (USD MILLION)
  • TABLE 296. AMERICAS CRISPR GENE EDITING MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2025-2032 (USD MILLION)
  • TABLE 297. AMERICAS CRISPR GENE EDITING MARKET SIZE, BY THERAPEUTIC, 2018-2024 (USD MILLION)
  • TABLE 298. AMERICAS CRISPR GENE EDITING MARKET SIZE, BY THERAPEUTIC, 2025-2032 (USD MILLION)
  • TABLE 299. AMERICAS CRISPR GENE EDITING MARKET SIZE, BY EX VIVO THERAPY, 2018-2024 (USD MILLION)
  • TABLE 300. AMERICAS CRISPR GENE EDITING MARKET SIZE, BY EX VIVO THERAPY, 2025-2032 (USD MILLION)
  • TABLE 301. AMERICAS CRISPR GENE EDITING MARKET SIZE, BY IN VIVO THERAPY, 2018-2024 (USD MILLION)
  • TABLE 302. AMERICAS CRISPR GENE EDITING MARKET SIZE, BY IN VIVO THERAPY, 2025-2032 (USD MILLION)
  • TABLE 303. AMERICAS CRISPR GENE EDITING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 304. AMERICAS CRISPR GENE EDITING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 305. AMERICAS CRISPR GENE EDITING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
  • TABLE 306. AMERICAS CRISPR GENE EDITING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2025-2032 (USD MILLION)
  • TABLE 307. AMERICAS CRISPR GENE EDITING MARKET SIZE, BY AGRICULTURAL COMPANIES, 2018-2024 (USD MILLION)
  • TABLE 308. AMERICAS CRISPR GENE EDITING MARKET SIZE, BY AGRICULTURAL COMPANIES, 2025-2032 (USD MILLION)
  • TABLE 309. AMERICAS CRISPR GENE EDITING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2024 (USD MILLION)
  • TABLE 310. AMERICAS CRISPR GENE EDITING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2025-2032 (USD MILLION)
  • TABLE 311. AMERICAS CRISPR GENE EDITING MARKET SIZE, BY PHARMA & BIOTECH COMPANIES, 2018-2024 (USD MILLION)
  • TABLE 312. AMERICAS CRISPR GENE EDITING MARKET SIZE, BY PHARMA & BIOTECH COMPANIES, 2025-2032 (USD MILLION)
  • TABLE 313. AMERICAS CRISPR GENE EDITING MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 314. AMERICAS CRISPR GENE EDITING MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
  • TABLE 315. AMERICAS CRISPR GENE EDITING MARKET SIZE, BY NON-VIRAL METHODS, 2018-2024 (USD MILLION)
  • TABLE 316. AMERICAS CRISP